SEC Form 4 · accession 0001140361-18-031328
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Debanjan Ray
Officer — Chief Financial Officer
Period of report
Jul 2, 2018
Accepted (ET)
Jul 3, 2018 · 6:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501989
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 2, 2018 | M | 3,000 | $1.2599 | A | 8,928 | D | |
| Common Stock | Jul 2, 2018 | S | 3,000 | $22.56 | D | 5,928 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.2599 | Jul 2, 2018 | M | 3,000 | D | — | Dec 10, 2023 | Common Stock | 3,000 | 2,710 | D |
Explanation of responses
- F1The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- F2100% of the shares subject to the option are fully vested and exercisable.